Underlying cardiopulmonary conditions as a risk factor for influenza and respiratory syncytial virus infection among community‐dwelling adults aged ≥ 65 years in Thailand: Findings from a two‐year prospective cohort study

Praphasiri, Prabda; Shrestha, Manash; Patumanond, Jayanton; Nakphook, Sutthichai; Chawalchitiporn, Sutthinan; Ditsungnoen, Darunee; Dawood, Fatimah S.; Mott, Joshua A.; Prasert, Kriengkrai

doi:10.1111/irv.12855

Cited by 9 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With RSV vaccines now available for older adults, data on RSV incidence in community- dwelling older adults can inform population impact and models evaluating the potential benefits of RSV vaccination programs in older adults, although few of these studies exist, particularly before the COVID-19 pandemic. 6,8,16,28,29 Prior studies identified RSV illness by passive surveillance only 29 or evaluated incidence based on both virologic and serologic confirmed infection. 8 Korsten et al (RESCEU study) assessed annual RSV community burden in about 500 older adults :260 years old from three cities in Europe between 2017–19 by weekly emails or calls to identify ARI, which was defined as having at least one of the following symptoms: cough, nasal congestion or discharge, wheezing or shortness of breath.…”

Section: Discussionmentioning

confidence: 99%

“…However, most of these studies have been conducted in households with children 6,[11][12][13] and in high-income countries. 14 Fewer were among older adults 15,16 including those aged ≥80 years, a group vulnerable to severe complications from these infections, 14 and in low-and-middle income countries. 12,[16][17][18] To address this gap, we established a community cohort of older adults in Jiangsu Province, China to characterize the incidence, symptom profiles, and medical care of PCR-confirmed influenza virus and RSV illnesses from December 2015-September 2017.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence, symptoms and medical care for influenza virus and respiratory syncytial virus illnesses among older adults in Eastern China: Findings from the China Ageing Respiratory Infections Study (CARES), 2015-2017

Leung,

Zhang,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

SUMMARYIntroductionFew studies have examined the incidence of virologic-confirmed influenza virus and respiratory syncytial virus (RSV) infections in community-dwelling older adults.MethodsWe enrolled adults aged 60–89 years in Jiangsu Province, China and followed them weekly from December 2015–September 2017 to identify acute respiratory illnesses (ARI), collect illness information and respiratory specimens for laboratory testing.Results1,527 adults were enrolled, 0·4% reported ever receiving influenza vaccination. 95 PCR-confirmed influenza ARIs and 22 RSV ARIs were identified, among whom 4–5% required hospitalization. One death associated with RSV ARI while none for influenza ARIs was observed. From December 2015-August 2016, the cumulative incidences of influenza and RSV ARIs were 0·8% (95% CI:0·3–1·4) and 0·5% (95% CI:0·1–1·0), respectively. From September 2016-August 2017, the cumulative incidences were 6·1% (95% CI:4·7–7·7) and 1·0% (95% CI:0·5–1·6); the influenza and RSV ARI-associated hospitalization incidences were 0·3% (95% CI:0–0·8) and 0·1% (95% CI:0–0·2). Feverishness was more common in influenza (55%) than RSV ARIs (30%, p=0·03). Influenza (12·5 days, p=0·02) and RSV ARI symptoms (14·1 days, p=0·15) lasted longer compared to PCR-negative/other ARIs (11·0 days). Antibiotic use was more common for influenza (65%, p=0·02) and RSV (70%, p=0·04) ARIs than other ARIs (51%).ConclusionsWe observed a higher incidence of influenza relative to RSV infections among community-dwelling older adults compared to prior studies. Our findings suggest older adults may benefit from receiving influenza and RSV vaccines to reduce the occurrence of illnesses.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Incidence, symptoms and medical care for influenza virus and respiratory syncytial virus illnesses among older adults in Eastern China: Findings from the China Ageing Respiratory Infections Study (CARES), 2015-2017

Leung,

Zhang,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Outbreaks of RSV in Thailand follow distinct spatiotemporal patterns with predictable seasonal timing and length [ 3 , 4 ]. During an RSV season, 60-70% of all children admitted with RSV infection are under the age of 12 months, while 80% are under the age of 2 years [ 5 - 7 ]. The clinical presentation of RSV infection usually begins with a runny nose, nasal congestion, and cough.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of Respiratory Syncytial Virus Infection in Hospitalized Children Before and During the COVID-19 Pandemic in Thailand

Malasao¹,

Chaiut²,

Sapbamrer³

et al. 2023

J Prev Med Public Health

View full text Add to dashboard Cite

Objectives: This study compared the epidemiological and clinical manifestations of patients hospitalized with respiratory syncytial virus (RSV) infection before and during the coronavirus disease 2019 (COVID-19) pandemic at a tertiary care hospital in Chiang Mai Province, Thailand.Methods: This retrospective observational study utilized data from all cases of laboratory-confirmed RSV infection at Maharaj Nakorn Chiang Mai Hospital from January 2016 to December 2021. Differences in the clinical presentation of RSV infection before (2016 to 2019) and during (2020 to 2021) the COVID-19 pandemic were analyzed and compared.Results: In total, 358 patients hospitalized with RSV infections were reported from January 2016 to December 2021. During the COVID-19 pandemic, only 74 cases of hospitalized RSV infection were reported. Compared to pre-pandemic levels, the clinical presentations of RSV infection showed statistically significant decreases in fever on admission (p=0.004), productive cough (p=0.004), sputum (p=0.003), nausea (p=0.03), cyanosis (p=0.004), pallor (p<0.001), diarrhea (p<0.001), and chest pain (p<0.001). Furthermore, vigilant measures to prevent the spread of COVID-19, including lockdowns, also interrupted the RSV season in Thailand from 2020 to 2021.Conclusions: The incidence of RSV infection was affected by the COVID-19 pandemic in Chiang Mai Province, Thailand, which also changed the clinical presentation and seasonal pattern of RSV infection in children.

show abstract

“…Older adults with underlying cardiorespiratory and endocrine or metabolic conditions (such as chronic obstructive pulmonary disease [COPD], congestive heart failure, and diabetes) are at increased risk of RSV-ARI [ 7 , 8 ]. This population often has more severe clinical presentations that may require medical care and may lead to hospitalization, exacerbation of underlying conditions, or death [ 5 , 7–19 ].…”

mentioning

confidence: 99%

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Feldman,

Antonelli-Incalzi,

Steenackers

et al. 2023

Clinical Infectious Diseases

View full text Add to dashboard Cite

Background Older adults with chronic cardiorespiratory or endocrine/metabolic conditions are at increased risk of respiratory syncytial virus (RSV)-related acute respiratory illness (RSV-ARI) and severe respiratory disease. In an ongoing, randomized, placebo-controlled, multicountry, phase 3 trial in ≥60-year-old participants, an AS01E-adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD), severe RSV-LRTD, and RSV-ARI. We evaluated efficacy and immunogenicity among participants with coexisting cardiorespiratory or endocrine/metabolic conditions that increase the risk of severe RSV disease (“conditions of interest”). Methods Medically stable ≥60-year-old participants received 1 dose of RSVPreF3 OA or placebo. Efficacy against first RSV-LRTD and RSV-ARI episodes was assessed in subgroups with/without coexisting cardiorespiratory or endocrine/metabolic conditions of interest. Immunogenicity was analyzed post hoc in these subgroups. Results In total, 12 467 participants received RSVPreF3 OA and 12 499 received placebo. Of these, 39.6% (RSVPreF3 OA) and 38.9% (placebo) had ≥1 coexisting condition of interest. The median efficacy follow-up was 6.7 months. Efficacy against RSV-LRTD was high in participants with ≥1 condition of interest (94.6%), ≥1 cardiorespiratory (92.1%), ≥1 endocrine/metabolic (100%), and ≥2 conditions of interest (92.0%). Efficacy against RSV-ARI was 81.0% in participants with ≥1 condition of interest (88.1% for cardiorespiratory, 79.4% for endocrine/metabolic conditions) and 88.0% in participants with ≥2 conditions of interest. Postvaccination neutralizing titers were at least as high in participants with ≥1 condition of interest as in those without. Conclusions RSVPreF3 OA was efficacious against RSV-LRTD and RSV-ARI in older adults with coexisting medical conditions associated with an increased risk of severe RSV disease. Clinical Trials Registration ClinicalTrials.gov: NCT04886596.

show abstract

Underlying cardiopulmonary conditions as a risk factor for influenza and respiratory syncytial virus infection among community‐dwelling adults aged ≥ 65 years in Thailand: Findings from a two‐year prospective cohort study

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 9 publications

References 25 publications

Incidence, symptoms and medical care for influenza virus and respiratory syncytial virus illnesses among older adults in Eastern China: Findings from the China Ageing Respiratory Infections Study (CARES), 2015-2017

Incidence, symptoms and medical care for influenza virus and respiratory syncytial virus illnesses among older adults in Eastern China: Findings from the China Ageing Respiratory Infections Study (CARES), 2015-2017

Characteristics of Respiratory Syncytial Virus Infection in Hospitalized Children Before and During the COVID-19 Pandemic in Thailand

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

Contact Info

Product

Resources

About